Janssen Scientific Affairs, LLC
166
18
37
88
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
19.3%
32 terminated/withdrawn out of 166 trials
73.3%
-13.2% vs industry average
28%
46 trials in Phase 3/4
63%
55 of 88 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (166)
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
Role: collaborator
Precise Infliximab Exposure and Pharmacodynamic Control
Role: collaborator
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
Role: collaborator
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
Role: collaborator
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
Role: collaborator
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
Role: collaborator
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
Role: collaborator
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Role: collaborator
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
Role: collaborator
Psoriasis Longitudinal Assessment and Registry
Role: lead
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
Role: collaborator
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
Role: lead
Multi-Center PAMPA Study
Role: collaborator
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Role: collaborator
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
Role: collaborator
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Role: collaborator
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
Role: collaborator
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Role: collaborator
Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy
Role: collaborator
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Role: collaborator